|
[1] URBAN S,SCHULZE A,DANDRI M,et al. The replication cycle of hepatitis B virus[J]. J Hepatol,2010,52(2):282-284.
|
|
[2] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.
|
|
[3] BLOCK TM,GUO H,GUO JT. Molecular virology of hepatitis B virus for clinicians[J]. Clin Liver Dis,2007,11(4):685-706.
|
|
[4] PRANGE R. Host factors involved in hepatitis B virus maturation,assembly,and egress[J]. Med Microbiol Immunol,2012,201(4):449-461.
|
|
[5] REGEV A,BERHO M,JEFFERS LJ,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection[J]. Am J Gastroenterol,2002,97(10):2614-2618.
|
|
[6] ROUSSELET MC,MICHALAK S,DUPRF,et al. Sources of variability in histological scoring of chronic viral hepatitis[J].Hepatology,2005,41(2):257-264.
|
|
[7] SORIANO V,BARREIRO P,BENITEZ L,et al. New antivirals for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs,2017,26(7):843-851.
|
|
[8] WANG J,DU M,HUANG H,et al. Reply to:“Serum HBV pgRNA as a clinical marker for cccDNA activity”:Consistent loss of serum HBV RNA might predict the “para-functional cure”of chronic hepatitis B[J]. J Hepatol,2017,66(2):462-463.
|
|
[9] WANG J,YU Y,LI G,et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol,2018,68(1):16-24.
|
|
[10] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.
|
|
[11] ALLWEISS L,LTGEHETMANN M,VOLZ T,et al. 42 pegylated-interferon-alpha alone or in combination with entecavir restores ISG responsiveness and reduces intrahepatic viral loads and antigenemia in hepatitis B virus infected humanized mice[J]. 2012,56(Suppl 2):s18-s19.
|
|
[12] BELLONI L,ALLWEISS L,GUERRIERI F,et al. IFN-αinhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest,2012,122(2):529-537.
|
|
[13] WIELAND SF,EUSTAQUIO A,WHITTEN-BAUER C,et al.Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids[J]. Proc Natl Acad Sci U S A,2005,102(28):9913-9917.
|
|
[14] HUANG YW,TAKAHASHI S,TSUGE M,et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy[J]. Antivir Ther,2015,20(4):369-375.
|
|
[15] LIMOTHAI U,CHUAYPEN N,POOVORAWAN K,et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat,2019,26(12):1481-1488.
|
|
[16] van BMMEL F,BARTENS A,MYSICKOVA A,et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology,2015,61(1):66-76.
|
|
[17] LUO H,TAN N,KANG Q,et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues[J].J Viral Hepat,2020,27(3):323-328.
|
|
[18] JANSEN L,KOOTSTRA NA,van DORT KA,et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis,2016,213(2):224-232.
|
|
[19] van BMMEL F,van BMMEL A,KRAUEL A,et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBe Ag-positive chronic hepatitis B[J]. J Infect Dis,2018,218(7):1066-1074.
|
|
[20] JIA W,ZHU MQ,QI X,et al. Serum hepatitis B virus RNA levels as a predictor of HBe Ag seroconversion during treatment with peginterferon alfa-2a[J]. Virol J,2019,16(1):61.
|
|
[21] TSUGE M,MURAKAMI E,IMAMURA M,et al. Serum HBV RNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol,2013,48(10):1188-1204.
|
|
[22] FAN R,ZHOU B,XU M,et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol,2020,18(3):719-727.
|
|
[23] ZHANG K,LIU Y,CHEN R,et al. Antigenicity reduction contributes mostly to poor detectability of HBs Ag by hepatitis B virus(HBV)S-gene mutants isolated from individuals with occult HBV infection[J]. J Med Virol,2018,90(2):263-270.
|
|
[24] KIM GA,LIM YS,AN J,et al. HBs Ag seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B:Clinical outcomes and durability[J]. Gut,2014,63(8):1325-1332.
|
|
[25] WANG J,CHEN X,WU Y,et al. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion[J]. Hepatol Commun,2018,2(10):1168-1171.
|
DownLoad: